Bisphosphonate use in acute and chronic spinal cord injury: A systematic review

Journal of Spinal Cord Medicine

Volumn 32, Issue 3, 2009, Pages 215-225

  Bryson, Julia E ^a   Gourlay, Margaret L ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Bisphosphonates; Bone density, tetraplegia; Heterotopic ossification; Osteoporosis; Paraplegia; Spinal cord injuries

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE;

ACUTE DISEASE; ACUTE DRUG ADMINISTRATION; BONE DENSITY; CHRONIC DISEASE; DRUG HALF LIFE; DRUG USE; FOLLOW UP; FRACTURE NONUNION; HUMAN; NONHUMAN; OSTEOPOROSIS; PARAPLEGIA; QUADRIPLEGIA; REVIEW; SPINAL CORD INJURY; SPINE FRACTURE; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 68549122668     PISSN: 10790268     EISSN: None     Source Type: Journal    
DOI: 10.1080/10790268.2009.11760776     Document Type: Review

References (32)

1. Eser P, Frotzler A, Zehnder Y, et al. Relationship between the duration of paralysis and bone structure: A pQCT study of spinal cord injured individuals. Bone. 2004;34(5):869-880. (Pubitemid 38581133)
2. Lazo MG, Shirazi P, Sam M, Giobbie-Hurder A, Blacconiere MJ, Muppidi M. Osteoporosis and risk of fracture in men with spinal cord injury. Spinal Cord. 2001;39(4):208-214. (Pubitemid 32574770)
3. Zehnder Y, Luthi M, Michel D, et al. Long-term changes in bone metabolism, bone mineral density, quantitative ultrasound parameters, and fracture incidence after spinal cord injury: a cross-sectional observational study in 100 paraplegic men. Osteoporos Int. 2004;15(3):180-189. (Pubitemid 38391532)
4. Hitzig SL, Tonack M, Campbell KA, et al. Secondary health complications in an aging Canadian spinal cord injury sample. Am J Phys Med Rehabil. 2008;87(7):545-555.
5. CDC, National Center for Injury Prevention and Control. Spinal cord injury (SCI): fact sheet. http://www.cdc.gov/ncipc/factsheets/scifacts.htm. Accessed March 15, 2009.
6. WHO Study Group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: report of a WHO study group. World Health Organ Tech Rep Ser. 1994;843:1-129.
7. Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008;19(4):385-397.
8. Comarr AE, Hutchinson RH, Bors E. Extremity fractures of patients with spinal cord injuries. Am J Surg. 1962;103(6):732-739.
9. Shields RK, Schlechte J, Dudley-Javoroski S, et al. Bone mineral density after spinal cord injury: a reliable method for knee measurement. Arch Phys Med Rehabil. 2005;86(10):1969-1973.
10. Jiang SD, Jiang LS, Dai LY. Mechanisms of osteoporosis in spinal cord injury. Clin Endocrinol (Oxf). 2006;65(5):555-565.
11. Giangregorio L, McCartney N. Bone loss and muscle atrophy in spinal cord injury: epidemiology, fracture prediction, and rehabilitation strategies. J Spinal Cord Med. 2006;29(5):489-500.
12. Mechanick JI, Liu K, Nierman DM, Stein A. Effect of a convenient single 90-mg pamidronate dose on biochemical markers of bone metabolism in patients with acute spinal cord injury. J Spinal Cord Med. 2006;29(4):406-412.
13. Wells GA, Cranney A, Peterson J, et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev. 2008;1:CD001155. (Pubitemid 351807494)
14. Cummings SR, Karpf DB, Harris F, et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med. 2002;112(4):281-289. (Pubitemid 34219441)
15. Kahn KS, terRiet G, Popay J, Nixon J, Kleijnen J. Undertaking systematic reviews of research on effectiveness: CRD's guidance for those carrying out or commissioning reviews. Phase 5: study quality assessment. http://www.york.ac.uk/ inst/crd/report4.htm. Accessed March 15, 2009.
16. Verhagen AP, de Vet HC, de Bie RA, et al. The delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by delphi consensus. J Clin Epidemiol. 1998;51(12):1235-1241.
17. Gilchrist NL, Frampton CM, Acland RH, et al. Alendronate prevents bone loss in patients with acute spinal cord injury: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab. 2007;92(4):1385-1390.
18. Shapiro J, Smith B, Beck T, et al. Treatment with zoledronic acid ameliorates negative geometric changes in the proximal femur following acute spinal cord injury. Calcif Tissue Int. 2007;80(5):316-322. (Pubitemid 46897445)
19. Pearson EG, Nance PW, Leslie WD, Ludwig S. Cyclical etidronate: its effect on bone density in patients with acute spinal cord injury. Arch Phys Med Rehabil. 1997;78(3):269-272. (Pubitemid 27120260)
20. Nance PW, Schryvers O, Leslie W, Ludwig S, Krahn J, Uebelhart D. Intravenous pamidronate attenuates bone density loss after acute spinal cord injury. Arch Phys Med Rehabil. 1999;80(3):243-251. (Pubitemid 29124741)
21. Bauman WA, Wecht JM, Kirshblum S, et al. Effect of pamidronate administration on bone in patients with acute spinal cord injury. J Rehabil Res Dev. 2005;42(3):305-313. (Pubitemid 41105826)
22. Moran de Brito CM, Battistella LR, Saito ET, Sakamoto H. Effect of alendronate on bone mineral density in spinal cord injury patients: a pilot study. Spinal Cord. 2005;43(6):341-348. (Pubitemid 40896043)
23. Zehnder Y, Risi S, Michel D, et al. Prevention of bone loss in paraplegics over 2 years with alendronate. J Bone Miner Res. 2004;19(7):1067-1074. (Pubitemid 41110557)
24. Hannan MT, Felson DT, Dawson-Hughes B, et al. Risk factors for longitudinal bone loss in elderly men and women: the Framingham osteoporosis study. J Bone Miner Res. 2000;15(4):710-720. (Pubitemid 30174025)
25. Orwoll ES, Bauer DC, Vogt TM, Fox KM. Axial bone mass in older women, study of osteoporotic fractures research group. Ann Intern Med. 1996;124(2):187-196.
26. Chappard D, Minaire P, Privat C, et al. Effects of tiludronate on bone loss in paraplegic patients. J Bone Miner Res. 1995;10(1):112-118.
27. Minaire P, Berard E, Meunier PJ, Edouard C, Goedert G, Pilonchery G. Effects of disodium dichloroethylene diphosphonate on bone loss in paraplegic patients. J Clin Invest. 1981;68(4):1086-1092. (Pubitemid 11023537)
28. Minaire P, Depassio J, Berard E, et al. Effects of clodronate on immobilization bone loss. Bone. 1987;8(suppl 1):S63-S68. (Pubitemid 18047659)
29. van den Berg-Emons RJ, Bussmann JB, Haisma JA, et al. A prospective study on physical activity levels after spinal cord injury during inpatient rehabilitation and the year after discharge. Arch Phys Med Rehabil. 2008;89(11):2094-2101.
30. Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006;144(10):753-761.
31. Cohen A, Shane E. Treatment of premenopausal women with low bone mineral density. Curr Osteoporos Rep. 2008;6(1):39-46.
32. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005;90(3):1294-1301. (Pubitemid 40463979)